SIGN UP
LOG IN
MARKET
NVO
NVO
Novo-Nordisk A/S
NYSE
100.40
-1.44
-1.41%
After Hours: 100.90 +0.5 +0.50% 19:52 12/01 EST
OPEN
101.10
PREV CLOSE
101.84
HIGH
101.76
LOW
100.31
VOLUME
4.57M
TURNOVER
0
52 WEEK HIGH
105.69
52 WEEK LOW
62.41
MARKET CAP
448.69B
P/E (TTM)
42.50
1D
5D
1M
3M
1Y
5Y
3 No-Brainer Growth Stocks to Buy in December
Three motley fool contributors suggest three growth stocks to buy in december. Eli lilly has the potential game-changing obesity drug zepbound. Novo nordisk is a weight loss drug company with a strong pipeline of new products. Vertex pharmaceuticals is a growth stock you should buy for the long term.
The Motley Fool · 21h ago
Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio
Abbott laboratories has outperformed the market over the past decade. The company has a recession-resilient business model and is poised for high single-digit returns in 2024. Abbott has a 1.83% yield and has 51 consecutive years of dividend increases. Abbott's leadership in value investing is a must-have in a defensive dividend growth portfolio.
Seeking Alpha · 1d ago
Weight loss drugs seen providing a boost to apparel stocks - Stifel
Consumer weight loss drugs seen providing a boost to apparel stocks - stifel. 15% of consumers are on glp-1 medications, according to a recent survey. Lululemon, levi's and dick's sporting goods could benefit from greater weight loss drug uptake.
Seeking Alpha · 1d ago
Everyone Is Talking About This Stock. Is It a Good Long-Term Option?
Danish drugmaker novo nordisk has a 33.3% share of the global diabetes care market. The company's key medicines in diabetes and obesity care are growing their sales rapidly. The drugmaker is looking to diversify its lineup and focus on alzheimer's and ad.
The Motley Fool · 1d ago
An Important History Lesson for Gene-Editing Investors
Weight-loss drugs and antibody-drug conjugates (adcs) are generating blockbuster sales and attracting major deals. Adcs are targeted anti-cancer therapies that are approved for various types of cancers. The weight-loss/adc market is expected to reach $20 billion in 2020.
The Motley Fool · 1d ago
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
Eli lilly and novo nordisk are competing for the same diabetes and obesity drug. Lilly's drug ozempic is approved for type 2 diabetes and wegovy for weight loss. Some analysts think lilly is a better stock to buy and hold over the next 10 years.
The Motley Fool · 1d ago
Novo Nordisk reportedly paid over $25M to doctors to promote obesity drugs
Reuters: novo nordisk paid at least $25.8m over ten years to doctors to promote obesity drugs. Payments were for speaking fees, consulting, travel and food, according to the news agency. Reuters only found payments in connection with weight-loss drugs approved for diabetes.
Seeking Alpha · 2d ago
Advocacy for Wegovy: Denmark Signals Cost-Sharing Talks While Novo Spent Millions On Medical Community For Drug Promotion
Denmark's health minister has signaled willingness to expand coverage for weight-loss drug wegovy. Novo nordisk aims to persuade european governments to subsidize the drug. Denmark's largest private health insurer has decided to cease reimbursement for the drug in 2024 due to high demand.
Benzinga · 2d ago
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Webull offers Novo Nordisk A/S (ADR) stock information, including NYSE: NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.